• Anesthesia for Ocular Surgery
• Ultrawide?field retinal selfie by smartphone, high-definition television, and a novel clip-on lens
• A perspective on the nature and frequency of pigment epithelial detachments
• Central retinal vein occlusion: modifying current treatment protocols
• Endpoint management: non-damaging laser therapy of the macula
• Multimodality imaging in macular telangiectasia 2: A clue to its pathogenesis
• Defining response to anti-VEGF therapies in neovascular AMD
• Telemedicine in Pediatric Retinal Disease
• Gas tamponade combined with laser photocoagulation therapy for congenital optic disc pit maculopathy
• Intravitreal bevacizumab for the treatment of chronic or recurrent central serous chorioretinopathy

Intravitreal bevacizumab for the treatment of chronic or recurrent central serous chorioretinopathy
Mitzy E. Torres Soriano. Open Journal of Ophthalmology Vol.4 No.3(2014), Article ID:48089,8 pages

Se presentan los resultados de una pequeña serie de casos con coroidopatía serosa central crónica o recurrente en los que se aplicó bevacizumab intravítreo. Se obtuvieron resultados favorables, en la mayoría de ellos con una dosis (1.25 mg/0.05 ml), se incrementó la agudeza visual y se redujo el desprendimiento de retina neurosensorial sin complicaiones sistémicas.